surfkast
5月前
Market Reaction & Analyst Sentiment:
VTYX stock significantly increased after the deal announcement, rising as much as 37%.
Analysts lowered price targets to $14, reflecting the certainty of the acquisition price.
Firms like UBS downgraded from Buy to Neutral, seeing limited upside beyond the offer price, though they maintain belief in Ventyx's pipeline value, as reported by Investing.com and MarketBeat.
surfkast
7月前
Global Healthcare Conference in London
By invitation only. You must be pre-registered by your Jefferies representative in order to attend.
New for 2025, Monday, November 17 will mark the launch of a focused Biotech/Biopharma Kick-off Day, while November 18 – 20 will continue to feature the full spectrum of the healthcare industry – including biopharma, biotech, specialty pharma, medical technology, healthcare services, healthcare IT, and other key sub-sectors.
The event will bring together C-Suite executives from leading public and private companies from around the globe and across diverse healthcare sub-sectors. In 2024, we hosted over 700 healthcare companies, 3,600 attendees, and 10,000 investor and business-to-business meetings.
https://www.jefferies.com/events/global-healthcare-conference-in-london/
surfkast
7月前
Using AI. Recent price targets and analyst ratings
Oppenheimer: Raised its price target to $14 from $9 and maintained an "Outperform" rating on October 27, 2025, after positive Phase 2 data for VTX3232.
Canaccord Genuity: Reiterated a "Buy" rating and a $14 price target on October 24, 2025.
Piper Sandler: Reiterated a "Buy" rating with a $21 price target on October 23, 2025.
Clear Street: Initiated coverage with a "Buy" rating and an $11 price target on October 1, 2025.
H.C. Wainwright: Reiterated a "Hold" rating on October 23, 2025.
Average price target and consensus rating
Due to the range of analyst opinions, different financial sites report varying average price targets.
$13.75: Based on an average of six Wall Street analysts' 12-month price targets from the past three months, as reported by TipRanks. This range has a low of $9.00 and a high of $21.00.
$12.39: An updated average one-year price target reported on October 29, 2025. This was an increase from a previous estimate of $11.22.
$11.50: A Zacks average based on short-term price targets from six analysts. The forecast range for this average is $2.00 to $21.00.
$10.00: MarketBeat's consensus price target, based on three analyst ratings (1 Buy, 1 Hold, 1 Sell). The firm gives Ventyx Biosciences a "Hold" consensus rating.
$10.00: According to StockAnalysis.com, two analysts covering the stock have a "Buy" consensus rating and an average price target of $10.
Analyst perspectives on VTYX
Analyst ratings on Ventyx reflect a wide range of outcomes. The recent upgrades and positive price target revisions from firms like Oppenheimer and Canaccord Genuity appear to be driven by positive Phase 2 clinical trial results. However, the continued existence of lower price targets and "Hold" or "Sell" ratings from other analysts and sources suggests some lingering caution.
Invest-in-America
1年前
Boy, some SAGE advice there, Bro!!! (And let alone the looming CRASH in that "Bitcoin" --- that digital GAMBLING CHIP, which represents NOTHING!! Not a sports team, not a commodity, not a precious metal, not an industry, not a nation, NOT ANYTHING!!! GOOD LUCK to those who 'INVEST" in any type of CRYPTO NOTHINGNESS!!! And ask the likes of the FDIC, etc., if they will INSURE your Bitcoin or Crypto nothingness account!!!)